India’s Pharmaceutical Industry: Why India Is Known as the Pharmacy of the World

Somewhere in the world right now, a patient is probably taking a medicine made in India. It could be a tablet from a small pharmacy in Africa or a prescription filled in the United States. That reach is why India is often called the “Pharmacy of the World.”

But the title isn’t only about how much the country produces. It’s about making good medicines at prices ordinary people can actually pay.

 

How Big Is India’s Pharmaceutical Industry?

 

Bigger than many people realise. India ranks third in the world for pharmaceutical production by volume and 11th by value. The market is worth around USD 60 billion and is expected to reach USD 130 billion by 2030. Generic medicines are where India really stands out. It’s the world’s largest supplier, providing about 20% of global supply through nearly 60,000 brands across 60 therapeutic categories. Indian medicines reach more than 200 countries, and exports hit a record USD 30.47 billion in FY 2024-25, the first time they had crossed USD 30 billion. Today, leading pharmaceutical companies in India contribute to this growth by supplying generic medicines, vaccines, healthcare products, and other essential treatments to domestic and international markets.

 

How Did India Earn the Title?

 

Much of the story goes back to the Patents Act of 1970. The law protected the process of making a medicine rather than the medicine itself, so Indian companies could find their own ways to produce existing drugs at a lower cost. Over the years, that opening grew into a strong generic manufacturing base and a skilled workforce. Low prices alone wouldn’t have earned the world’s trust, though. Quality had to keep up. India now has more USFDA-approved plants than any other country outside the United States, and its companies sell into tightly regulated markets such as the US, the UK, and Europe. India’s role goes well beyond tablets and capsules, too. It supplies a significant share of the essential vaccines used in immunisation programmes supported by UNICEF and the World Health Organization. It also accounts for nearly 8% of the global industry for active pharmaceutical ingredients (APIs), the substances that make a medicine work. 

 

The Role of Pharmaceutical Companies in India’s Healthcare Growth

 

The success of India’s pharmaceutical industry is not limited to large-scale manufacturers. Pharmaceutical companies also play an important role in making medicines available through distribution networks, marketing partnerships, franchise opportunities, and different therapeutic product segments. Companies working across neurology, psychiatry, cardiac care, diabetes, dermatology, and general healthcare help expand access to a wider range of treatment options. One such name is Psychocare Health Pvt. Ltd., a Mohali-based pharmaceutical company established in 2013. Psychocare has developed its presence in the Indian pharmaceutical industry with a strong focus on neuropsychiatry medicines and an expanding portfolio across multiple healthcare segments. Today, Psychocare offers more than 1,400 products across therapeutic categories such as neurology, psychiatry, cardiac-diabetic care, dermatology, gynaecology, and wellness. Through its divisions, including PCHPL, Mind In Peace, TAS Derma, PCHPL Wellness, Just Awe, and others, the company serves different healthcare and wellness requirements. Psychocare also contributes to the pharmaceutical business ecosystem by working with manufacturing partners, supporting distributors, and offering PCD pharma franchise opportunities across India. Its network of 500+ distributors and institutions reflects its growing presence in the market.

 

What Comes Next?

 

For all its strength in volume, India still has plenty of room to grow in value. NITI Aayog puts the country’s share of global pharmaceutical and API exports at just 2.8%, and India still relies heavily on imported inputs. The think tank’s advice is that the next phase of growth should come from high-value products, not just high volumes. That will take more investment in research and more production of key raw materials at home. Pharmaceutical companies will also need to focus on quality, innovation, stronger distribution networks, and better healthcare solutions. 

Fill the form and we will contact you